Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Antiviral drug being evaluated in two Phase III trials in patients with severe and moderate manifestations
March 13, 2020
By: Kristin Brooks
Managing Editor, Contract Pharma
According to a World Health Organization official, Gilead’s experimental antiviral drug remdesivir, to date, shows the most promise for treating COVID-19 disease.
Remdesivir is an investigational nucleotide analog with broad-spectrum antiviral activity. Although it is not currently approved for use, Remdesivir has demonstrated in vitro and in vivo activity in animal models against the viral pathogens MERS and SARS, which are also coronaviruses and are structurally similar to COVID-19. The limited preclinical data on remdesivir in MERS and SARS indicate that remdesivir may have potential activity against COVID-19.
Gilead has initiated two Phase III trials to evaluate the safety and efficacy of remdesivir in adults diagnosed with COVID-19 following the U.S. FDA’s rapid review and acceptance of Gilead’s investigational IND filing. These studies will enroll approximately 1,000 patients primarily across Asian countries, as well as other countries globally with high numbers of diagnosed cases.
The first of two studies will evaluate both a 5-day and a 10-day dosing regimen of remdesivir for patients with severe manifestations of COVID-19. The second study will evaluate the safety and efficacy for patients with moderate manifestations of COVID-19, compared with standard of care alone.
Gilead is working with government and other organizations and regulatory authorities to provide remdesivir to patients with COVID-19 for emergency treatment in the absence of any approved treatment options.
There are currently limited available clinical supplies of remdesivir but Gilead is working to increase its available supply as rapidly as possible.
In response to the Ebola outbreaks in West Africa in recent years, Gilead increased manufacturing of remdesivir to create a stockpile of product that could be used in response to future pandemics, as well as a stockpile of materials used to manufacture remdesivir. Gilead is now using this stockpile to address the supply needed for current compassionate use requests and the two clinical trials in China.
In anticipation of potential future needs, Gilead has accelerated manufacturing timelines to increase available supply as rapidly as possible. Gilead is taking these actions before knowing whether remdesivir will be determined to be safe and effective to treat patients with COVID-19.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !